EyeGate Pharmaceuticals appoints three executives
Sarah Romano, Corporate Controller, has been named Interim Chief Financial Officer.
Ms. Romano joined EyeGate Pharmaceuticals as Corporate Controller in 2016, and has been responsible for the Company's accounting, tax, financial reporting, and internal controls.
Prior to joining EyeGate, Ms. Romano served as Assistant Controller at TechTarget and Corporate Controller at Bowdoin Group, a healthcare-focused executive recruiting firm.
Previously, Ms. Romano held financial reporting positions of increasing responsibility at SoundBite Communications until its acquisition by Genesys in 2013, and was a Senior Financial Reporting Analyst at Cognex Corporation, a publicly-traded manufacturer of machine vision systems, software and sensors.
Ms. Romano began her career as an Auditor in the Boston office of PricewaterhouseCoopers.
A licensed CPA in Massachusetts, she holds a Bachelor of Arts in Accounting from College of the Holy Cross and Masters of Accounting from Boston College.
Lisa Brandano has been promoted from Director, Clinical Operations to Vice President, Clinical Operations.
Ms. Brandano joined EyeGate in 2011, and has served as Associate Director and Director of Clinical Operations.
Prior to joining EyeGate, Ms. Brandano served as Assistant Managing Director of the Boston Office and Director of Clinical Trial Operations at CATO Research, an international contract research organization.
During her 11 years with CATO, she was involved in the oversight and facilitation of global clinical operations.
Previously, she held clinical research coordinator and laboratory science roles at Beth Israel Deaconess Medical Center in Boston.
Ms. Brandano holds a BS in biology from Emmanuel College, and since 2003, she has been a certified clinical research associate (CRA) with the Association of Clinical Research Professionals (ACRP).
Carol Assang, Associate Director, Clinical Operations has been named Director, Clinical Operations.
Ms. Assang joined EyeGate in 2010, and has been responsible for all aspects of clinical study planning and the execution of multiple clinical development programs.
Prior to joining EyeGate, Ms. Assang served as an Associate Project Director/Senior Clinical Associate at New England Research Institutes, where she was responsible for clinical development and operations of several programs.
Previously, Ms. Assang served as Program Manager at Harvard Clinical Research Institute, Clinical Studies Coordinator at Tufts-New England Medical Center, Associate Medical Program Coordinator at Merck and a Consultant at Alliance Pharmaceuticals.
She holds a Bachelor’s degree in Chemistry and Mathematics from Wesleyan University and Master’s Degree in Chemistry from Yale University. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST
FedEx Corporation Q1 income down 10% Earnings